Claritin, Pseudoephedrine Sales Impact Schering Consumer Health Revenue
This article was originally published in The Tan Sheet
Executive Summary
Sales for the Clarinex and Claritin prescription business decreased 4% during the third quarter to $233 mil., Schering-Plough Executive VP - Global Pharmaceuticals President Carrie Cox stated in an Oct. 24 third-quarter earnings call
You may also be interested in...
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Chattem’s Financing Strategy Keeps Door Open For Acquisitions
Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth